TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24998653
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg q.d for 1 year)
Study: 22402864
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 20 mg/kg/day for 12 months
Study: 11248182
Drug: Cytokine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine therapy (growth factor treatment)
Study: 26081328
Drug: Ibuprofen (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200-400 mg/day) + Tizanidine (2-4 mg/day) + Anvifen (750 mg/day) for 8 weeks
Study: 26081328
Drug: Ibuprofen (200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (200-400 mg/day) + Tizanidine (2-4 mg/day)
Study: 25040039
Drug: AQX-1125 (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQX-1125 (450 mg daily)
Study: 19916252
Drug: Ropivacaine 0.375%
Normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.375% (20 mL)
Study: 19916252
Drug: Placebo (saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline, 20 mL)
Study: 20088941
Drug: Acarbose up
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose up to 100 mg three times a day
Study: 11598842
Drug: Yeast-derived HPV-11
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived HPV-11 L1 VLP vaccine
Study: 2846132
Drug: Propranolol 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 320 mg daily
Study: 2846132
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg daily
Study: 27236150
Drug: Telaprevir-based triple
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir-based triple therapy
Study: 17509246
Drug: Disease-modifying drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying drugs
Study: 14711840
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg/12 h)
Study: 14711840
Drug: Teicoplanin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (400 mg/12 h for three doses then 400 mg/24 h)
Study: 8103027
Drug: Ranitidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine infusion (up to 600 mg/24 hours)
Study: 30595526
Drug: JR‐141 (iduronate-2-sulfatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: JR‐141 (iduronate-2-sulfatase fused with anti-human transferrin receptor antibody)
Study: 27422891
Drug: Toreforant 100
Normalized name: Toreforant
DrugBank: Toreforant (DB12522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toreforant 100 mg/day
Study: 27422891
Drug: Toreforant 3/10/30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toreforant 3/10/30 mg
Study: 18042508
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) with 3 agents for 48 weeks
Study: 12133187
Drug: Physiological-dose steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological-dose steroid therapy for 10 days
Study: 7540397
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (30,000 KIU/kg in CPB priming volume and 7,500 KIU/kg intravenously each hour during CPB)
Study: 2228396
Drug: dexfenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexfenfluramine (30 mg/day)
Study: 31658479
Drug: Interventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventional treatment strategies for secondary MR
Study: 28148502
Drug: Intragastric administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric administration of 1 μmol DB/kg
Study: 16904537
Drug: Caffeine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (10 mg/l)
Study: 15167288
Drug: Triple-nucleoside therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-nucleoside therapy (ZDV, 3TC, and ddI)
Study: 15167288
Drug: Dual-nucleoside therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-nucleoside therapy (ZDV and 3TC or ddI and d4T)
Study: 2885337
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (25 mU/m2 X min)
Study: 2885337
Drug: Insulin with
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin with SRIH (250 micrograms/h) and glucagon replacement (0.4 ng/kg X min)
Study: 30255302
Drug: Simvastatin (Zocor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (Zocor – MSD; 40 mg daily)
Study: 29626465
Drug: 12-month adjuvant
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month adjuvant androgen-deprivation therapy (ADT)
Study: 25391138
Drug: Ferrous gluconate
Normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous gluconate in a capsule
Study: 25391138
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cola jelly and calcium
Study: 9386673
Drug: RRV‐TV (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV‐TV (4 x 10(5) plaque‐forming units per dose)
Study: 9386673
Drug: RRV‐S1 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRV‐S1 (4 x 10(5) plaque‐forming units per dose)
Study: 22411021
Drug: Monthly automated
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly automated telephone calls reminding to take glaucoma medications and a 1-time educational session with a physician.
Study: 16132877
Drug: ML-1 standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML-1 standardized mistletoe extract (1 ng/kg body weight, injected subcutaneously twice weekly for 60 weeks)
Study: 10910490
Drug: remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil infusion titrated to autonomic responses
Study: 8764802
Drug: Placebos (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos (oral and intravenous)
Study: 1395837
Drug: BBPRI vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBPRI vaccine
Study: 1395837
Drug: BBPRI vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBPRI vaccine plus HBIG
Study: 12916869
Drug: Iseganan 9
Normalized name: Iseganan
DrugBank: Iseganan (DB16010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iseganan 9 mg, oral rinse, swished/swallowed 6 times daily for 21-28 days
Study: 12916869
Drug: Placebo, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral rinse, swished/swallowed 6 times daily for 21-28 days
Study: 10617707
Drug: Midazolam nasal
Normalized name: midazolam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam nasal spray (0.2 mg/kg body weight)
Study: 8885584
Drug: Methylphenidate (individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (individual titration to 'best' dose)
Study: 3878631
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies including Sucralfate
Study: 25932849
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefazolin
Study: 25932849
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g cefazolin
Study: 17407626
Drug: paroxetine 40
Normalized name: PARoxetine 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: paroxetine 40 mg/day
Study: 15159237
Drug: Fruveg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruveg group (600 g fruit and vegetables/d)
Study: 15159237
Drug: Supplement group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement group (vitamin pill corresponding to 600 g fruit and vegetables)
Study: 15159237
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (placebo pill)
Study: 15159237
Drug: Supplement group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement group
Study: 15159237
Drug: Fruveg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruveg group and Supplement group
Study: 16967629
Drug: Unopposed E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed E2 1 mg
Study: 10960628
Drug: E2-norethindrone acetate
Normalized name: Norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2-norethindrone acetate 0.1 mg
Study: 10960628
Drug: E2-norethindrone acetate
Normalized name: Norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2-norethindrone acetate 0.25 mg
Study: 10960628
Drug: E2-norethindrone acetate
Normalized name: Norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2-norethindrone acetate 0.5 mg
Study: 1310645
Drug: Soya fibers
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya fibers (7 g)
Study: 1310645
Drug: Cellulose (7
Normalized name: ethylcellulose (7 MPA.S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose (7 g)
Study: 6239881
Drug: compound tincture
Normalized name: Compound tincture benzoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: compound tincture of benzoin
Study: 26797802
Drug: Imatinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib therapy
Study: 27751589
Drug: 7.5mg oral
Normalized name: Iron 37.5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5mg oral paroxetine
Study: 22421064
Drug: Augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation with olanzapine (RIS+OLZ group)
Study: 22421064
Drug: Increased risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Increased risperidone dose (RIS+RIS group)
Study: 16192774
Drug: Intravenous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treatment (lidocaine-sufentanil-clonidine)
Study: 16192774
Drug: Postoperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative epidural treatment (intravenous-epidural)
Study: 16192774
Drug: Intraoperative epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative epidural treatment (epidural-epidural and epidural-intravenous)
Study: 12519409
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine oestrogens
Study: 12519409
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐oestradiol
Study: 12519409
Drug: Oral 17
Normalized name: polyoxypropylene (17)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 17 beta‐oestradiol followed by sequential oestrogen‐progestogen HRT (17 beta‐oestradiol and dydrogesterone)
Study: 10759926
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A, 100 units, diluted in 1 mL of saline
Study: 10759926
Drug: Saline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1 mL)
Study: 8641826
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of oral zinc sulfate once daily for 24 months
Study: 28911062
Drug: TPF-E (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF-E (cisplatin and docetaxel 75mg/m2 on day 1 followed by 5-FU 750mg/m2/day as a continuous infusion on days 1-5 plus cetuximab at a loading dose of 400mg/m2 followed by a weekly dose of 250mg/m2)
Study: 28911062
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin 40mg/m2
Study: 28911062
Drug: Weekly carboplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly carboplatin, AUC of 1.5mg/ml/min
Study: 28911062
Drug: Radiotherapy (70Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (70Gy over 7 weeks in 2Gy fractions) with weekly cetuximab
Study: 26031148
Drug: Methotrexate monotherapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate monotherapy (5-20 mg weekly)
Study: 15741251
Drug: Ganirelix (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganirelix (selective GnRH-receptor antagonist)
Study: 9804024
Drug: Cochlear implants
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implants (CI), post-operative period
Study: 7614643
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg plus sodium citrate
Study: 7614643
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg plus sodium citrate
Study: 2693542
Drug: Lomefloxacin (LFLX)
DrugBank: Lomefloxacin (DB00978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lomefloxacin (LFLX) 600 mg/day for 5 days
Study: 2693542
Drug: Pipemidic acid
Normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipemidic acid (PPA) 2000 mg/day for 5 days
Study: 38806
Drug: Long-term neuroleptic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term neuroleptic treatment (individually adjusted dosage)
Study: 38806
Drug: Long-term neuroleptic
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term neuroleptic treatment
Study: 28935470
Drug: RV5 (pentavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: RV5 (pentavalent live human-bovine reassortant rotavirus vaccine)
Study: 23138396
Drug: N-acethyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acethyl-cysteine (NAC) 600 mg twice daily the day before and the day of the procedure plus 154 mmol NaHCO3 solution (B0) at a rate of 3 ml/kg/h from at least 2 h before the procedure and at 1 ml/kg/h during and for the next 6-12 h (BN group)
Study: 23138396
Drug: 154 mmol
Normalized name: sodium chloride 0.154 MEQ/ML [Saljet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 154 mmol NaHCO3 solution (B0) at a rate of 3 ml/kg/h from at least 2 h before the procedure and at 1 ml/kg/h during and for the next 6-12 h (B0 group)
Study: 23138396
Drug: N-acethyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acethyl-cysteine (NAC) as above plus 154 mmol NaCl solution at a rate of 3 ml/kg/h from at least 2 h before the procedure and at 1 ml/kg/h during and for the next 6-12 h (SN group)
Study: 19002646
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using two diode laser probes (660 nm, 6.2 J/cm², 6 min, continuous wave; 890 nm, 1 J/cm², 10 min, 1,500 Hz)
Study: 19002646
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo treatment, similar procedure without irradiation)
Study: 10786260
Drug: Pharmacist outreach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist outreach program with academic detailing on ACE inhibitors and angiotensin II-receptor inhibitors for CHF.
Study: 10786260
Drug: Patients treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with an ACE inhibitor for CHF.
Study: 8353101
Drug: Post-operative local
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative local chemotherapy (intraportal)
Study: 8353101
Drug: Post-operative radiation
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative radiation therapy with chemotherapy
Study: 8353101
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent systemic chemotherapy
Study: 2874738
Drug: AC-DTP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC-DTP vaccine
Study: 21538700
Drug: bihemispheric transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: bihemispheric transcranial direct current stimulation and simultaneous physical/occupational therapy for five consecutive days
Study: 16225490
Drug: Oral esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral esomeprazole
Study: 7756468
Drug: Ritipenem acoxil
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritipenem acoxil (500 mg three times daily)
Study: 7756468
Drug: Norfloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (200 mg twice daily)
Study: 2144788
Drug: 0.18 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18 mg/kg ondansetron (high dose)
Study: 2144788
Drug: 0.01 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg/kg ondansetron (low dose)
Study: 7286585
Drug: Cabernet Sauvignon
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabernet Sauvignon (mean ethanol concentration = 9500 mg/dl)
Study: 7286585
Drug: Low-alcohol Cabernet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-alcohol Cabernet Sauvignon (mean ethanol concentration = 1312 mg/dl)
Study: 29071331
Drug: Dalcetrapib, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalcetrapib, 600 mg daily
Study: 22537990
Drug: Healive (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healive (one dose)
Study: 22537990
Drug: Havrix (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix (one dose)
Study: 22537990
Drug: Healive (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healive (two doses)
Study: 22537990
Drug: Havrix (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix (two doses)
Study: 22537990
Drug: Healive-Havrix (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healive-Havrix (two doses)
Study: 22537990
Drug: Havrix-Healive (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix-Healive (two doses)
Study: 17566515
Drug: Glucan solution
Normalized name: BETA GLUCAN
DrugBank: Yeast beta-D-glucan (DB19271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucan solution nasal spray
Study: 11996634
Drug: Newer antidepressant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antidepressant medications (including serotonergic antidepressants and buspirone)
Study: 11996634
Drug: Benzodiazepines and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepines and tricyclic antidepressants (TCAs)
Study: 10488969
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 IU daily for 8 weeks)
Study: 8730557
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy plus drug resistance modifying agents such as cyclosporins
Study: 6861873
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release (CR) formulation of indomethacin 75 mg (Indocid‐Retard) given once daily
Study: 6861873
Drug: Conventional 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 25 mg indomethacin capsule (Indocid) given 3 times daily
Study: 31730506
Drug: Community-based interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based interventions (exercise, medication, nutritional management, improving safety of the local environment)
Study: 29381666
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus MPA (2.5 mg/d)
Study: 29381666
Drug: CEE plus
Normalized name: Ecee Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE plus MPA (2.5 mg/d) postintervention
Study: 29381666
Drug: CEE (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (0.625 mg/d) postintervention
Study: 1776335
Drug: Molsidomine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (16 mg, slow-release formulation)
Study: 31869756
Drug: Standardised medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised medical (including psychiatric) care + cognitive behavioural therapy for dissociative seizures (part of the CODES trial)
Study: 17060331
Drug: Propofol 4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 4 mug ml(‐1)
Study: 10701625
Drug: 250 mg/ml
Normalized name: urea 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/ml (1250)
Study: 10701625
Drug: 300 mg/ml
Normalized name: urea 300 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/ml (1300)
Study: 10701625
Drug: 350 mg/ml
Normalized name: urea 350 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 mg/ml (1350)
Study: 3028362
Drug: Beta Interferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta Interferon cream (20,000 iu/g)
Study: 24311828
Drug: Wu-Ling-San (WLS)
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wu-Ling-San (WLS) formula, 2 gm three times daily for 1 month
Study: 24311828
Drug: Placebo, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 gm three times daily for 1 month
Study: 21865574
Drug: ATRA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRA (20 mg/m²/d)
Study: 21865574
Drug: ATRA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATRA (20 mg/kg PO) in animal model
Study: 19659873
Drug: Oral procyanidin
Normalized name: procyanidin A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral procyanidin + vitamins A, C, E
Study: 11843249
Drug: SIR-Spheres plus
Normalized name: INCONT BRIEF SIR DIGNITY PLUS LARGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIR-Spheres plus chemotherapy (HAC)
Study: 9684188
Drug: Oral specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral specific hyposensitization treatment
Study: 7849967
Drug: Fluosol DA-20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluosol DA-20% (FDA) intravenous infusion at 30 cc/kg